Does the media prefer RVMD or VRTX?

In the previous week, Revolution Medicines had 1 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 9 mentions for Revolution Medicines and 8 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.75 beat Revolution Medicines' score of 0.14 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vertex Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor REGN or RVMD?

In the previous week, Regeneron Pharmaceuticals had 16 more articles in the media than Revolution Medicines. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 9 mentions for Revolution Medicines. Regeneron Pharmaceuticals' average media sentiment score of 0.39 beat Revolution Medicines' score of 0.14 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 5 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRNA or RVMD?

In the previous week, Moderna had 30 more articles in the media than Revolution Medicines. MarketBeat recorded 39 mentions for Moderna and 9 mentions for Revolution Medicines. Moderna's average media sentiment score of 0.25 beat Revolution Medicines' score of 0.14 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 9 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARGX or RVMD?

In the previous week, argenex had 10 more articles in the media than Revolution Medicines. MarketBeat recorded 19 mentions for argenex and 9 mentions for Revolution Medicines. argenex's average media sentiment score of 0.21 beat Revolution Medicines' score of 0.14 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RVMD or NTRA?

In the previous week, Natera had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 21 mentions for Natera and 9 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.14 beat Natera's score of 0.13 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Revolution Medicines (RVMD) Competitors

$190.64 +2.52 (+1.34%)

As of 02:27 PM Eastern

Compare

RVMD vs. VRTX, REGN, MRNA, ARGX, and NTRA

Should you buy Revolution Medicines stock or one of its competitors? Revolution Medicines's main competitors and comparable companies include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), argenex (ARGX), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Revolution Medicines (NASDAQ:RVMD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Revolution Medicines had 1 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 9 mentions for Revolution Medicines and 8 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.75 beat Revolution Medicines' score of 0.14 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vertex Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Revolution Medicines currently has a consensus target price of $234.76, suggesting a potential upside of 24.79%. Vertex Pharmaceuticals has a consensus target price of $575.39, suggesting a potential upside of 14.34%. Given Revolution Medicines' higher probable upside, equities analysts plainly believe Revolution Medicines is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Vertex Pharmaceuticals has a net margin of 35.00% compared to Revolution Medicines' net margin of 0.00%. Vertex Pharmaceuticals' return on equity of 23.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Vertex Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A
Vertex Pharmaceuticals	$12.00B	10.64	$3.95B	$17.18	29.29

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Revolution Medicines' net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Revolution Medicines	N/A	-88.20%	-57.85%

In the previous week, Regeneron Pharmaceuticals had 16 more articles in the media than Revolution Medicines. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 9 mentions for Revolution Medicines. Regeneron Pharmaceuticals' average media sentiment score of 0.39 beat Revolution Medicines' score of 0.14 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	5 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Regeneron Pharmaceuticals currently has a consensus price target of $817.92, indicating a potential upside of 10.59%. Revolution Medicines has a consensus price target of $234.76, indicating a potential upside of 24.79%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

Regeneron Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.31	$4.50B	$40.46	18.28
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A

Summary

Regeneron Pharmaceuticals beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Moderna?

Moderna (NASDAQ:MRNA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

75.3% of Moderna shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Revolution Medicines has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	40.46	-$2.82B	-$7.99	N/A
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A

Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Revolution Medicines	N/A	-88.20%	-57.85%

Moderna presently has a consensus target price of $78.17, indicating a potential downside of 60.32%. Revolution Medicines has a consensus target price of $234.76, indicating a potential upside of 24.79%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Moderna had 30 more articles in the media than Revolution Medicines. MarketBeat recorded 39 mentions for Moderna and 9 mentions for Revolution Medicines. Moderna's average media sentiment score of 0.25 beat Revolution Medicines' score of 0.14 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	9 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Revolution Medicines beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

argenex (NASDAQ:ARGX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$5.23B	9.80	$1.29B	$26.04	31.44
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A

argenex has a net margin of 32.19% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 43.59% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Revolution Medicines	N/A	-88.20%	-57.85%

In the previous week, argenex had 10 more articles in the media than Revolution Medicines. MarketBeat recorded 19 mentions for argenex and 9 mentions for Revolution Medicines. argenex's average media sentiment score of 0.21 beat Revolution Medicines' score of 0.14 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

60.3% of argenex shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

argenex currently has a consensus price target of $1,158.61, indicating a potential upside of 41.53%. Revolution Medicines has a consensus price target of $234.76, indicating a potential upside of 24.79%. Given argenex's higher probable upside, equities analysts clearly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

argenex beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Natera?

Revolution Medicines (NASDAQ:RVMD) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Revolution Medicines presently has a consensus target price of $234.76, indicating a potential upside of 24.79%. Natera has a consensus target price of $353.45, indicating a potential downside of 9.55%. Given Revolution Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Revolution Medicines is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Natera had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 21 mentions for Natera and 9 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.14 beat Natera's score of 0.13 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natera	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Natera has higher revenue and earnings than Revolution Medicines. Natera is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A
Natera	$2.31B	24.43	-$208.16M	-$1.36	N/A

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Natera has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.38% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Natera	-7.11%	-11.38%	-7.87%

Summary

Natera beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.84B	$3.90B	$7.21B	$13.27B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-21.61	13.85	274.52	26.15
Price / Sales	N/A	1,189.36	585.83	81.10
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	22.59	17.14	11.21	6.33
Net Income	-$1.13B	-$22.69M	$3.50B	$381.74M
7 Day Performance	-7.74%	-1.04%	-0.78%	-1.36%
1 Month Performance	-8.20%	-9.63%	-5.37%	-4.29%
1 Year Performance	300.34%	10.49%	4.65%	-0.24%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	3.5782 of 5 stars	$190.64 +1.3%	$234.76 +23.1%	+293.4%	$40.84B	N/A	N/A	883	Analyst Forecast
VRTX Vertex Pharmaceuticals	3.7898 of 5 stars	$527.67 +0.3%	$575.13 +9.0%	+19.5%	$133.55B	$12.00B	30.71	6,400	Positive News Analyst Forecast
REGN Regeneron Pharmaceuticals	4.2475 of 5 stars	$752.25 -4.5%	$802.18 +6.6%	+31.2%	$81.13B	$14.34B	18.59	15,410	Analyst Forecast
MRNA Moderna	1.9483 of 5 stars	$197.28 -0.8%	$76.72 -61.1%	+605.6%	$79.40B	$1.94B	N/A	4,700	Trending News Analyst Forecast
ARGX argenex	4.7051 of 5 stars	$972.25 +1.3%	$1,158.61 +19.2%	+2.5%	$60.03B	$4.25B	37.34	1,863	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, MRNA, ARGX, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Summary

How does Revolution Medicines compare to Moderna?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Natera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, MRNA, ARGX, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Does the media prefer RVMD or VRTX?

Which has more risk & volatility, RVMD or VRTX?

Do analysts recommend RVMD or VRTX?

Is RVMD or VRTX more profitable?

Which has preferable valuation & earnings, RVMD or VRTX?

Do insiders and institutionals believe in RVMD or VRTX?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Is REGN or RVMD more profitable?

Does the media favor REGN or RVMD?

Do institutionals & insiders believe in REGN or RVMD?

Do analysts prefer REGN or RVMD?

Which has more volatility and risk, REGN or RVMD?

Which has better earnings & valuation, REGN or RVMD?

Summary

How does Revolution Medicines compare to Moderna?

Do institutionals and insiders believe in MRNA or RVMD?

Which has better valuation and earnings, MRNA or RVMD?

Which has more risk and volatility, MRNA or RVMD?

Is MRNA or RVMD more profitable?

Do analysts recommend MRNA or RVMD?

Does the media favor MRNA or RVMD?

Summary

How does Revolution Medicines compare to argenex?

Which has preferable valuation and earnings, ARGX or RVMD?

Is ARGX or RVMD more profitable?

Does the media refer more to ARGX or RVMD?

Which has more volatility & risk, ARGX or RVMD?

Do insiders and institutionals believe in ARGX or RVMD?

Do analysts rate ARGX or RVMD?

Summary

How does Revolution Medicines compare to Natera?

Do analysts rate RVMD or NTRA?

Does the media refer more to RVMD or NTRA?

Do insiders & institutionals believe in RVMD or NTRA?

Which has stronger earnings & valuation, RVMD or NTRA?

Which has more volatility and risk, RVMD or NTRA?

Is RVMD or NTRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools